Cabaletta Bio
CABA
120 hedge funds and large institutions have $227M invested in Cabaletta Bio in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 35 reducing their positions, and 41 closing their positions.
64% more call options, than puts
Call options by funds: $992K | Put options by funds: $604K
34% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 35
6.86% less ownership
Funds ownership: 105.22% → 98.36% (-6.9%)
15% less funds holding
Funds holding: 142 → 120 (-22)
40% less capital invested
Capital invested by funds: $380M → $227M (-$153M)
54% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 41
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$9.24M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$6.43M |
| 3 |
Millennium Management
New York
|
+$5.38M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.86M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$19.6M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$9.38M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.42M |
| 4 |
PA
Perceptive Advisors
New York
|
-$4.38M |
| 5 |
JP Morgan Chase
New York
|
-$3.92M |
CABA Hedge Fund Activity: Q3 2024 in Review
120 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q3 2024, worth a combined $227M — down 40% from $380M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CABA and 19 opened new positions — a net loss of 22 holders — while 35 trimmed existing stakes and 47 added.
The largest buyer was Fred Alger Management, adding an estimated $9.24M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $19.6M sold.
- 120 institutional investors held Cabaletta Bio (CABA) as of Q3 2024, down from 142 in Q2 2024.
- Funds reported $227M of Cabaletta Bio stock for Q3 2024, down 40% quarter-over-quarter.
- 19 funds opened new Cabaletta Bio positions in Q3 2024 and 41 closed out, a net change of -22 holders.
- The largest Cabaletta Bio buyer in Q3 2024 was Fred Alger Management, an estimated $9.24M added.
- The largest Cabaletta Bio seller in Q3 2024 was Alkeon Capital Management, an estimated $19.6M sold.
Based on aggregated 13F filings for Q3 2024.